全文获取类型
收费全文 | 15403篇 |
免费 | 3214篇 |
国内免费 | 262篇 |
专业分类
耳鼻咽喉 | 743篇 |
儿科学 | 381篇 |
妇产科学 | 306篇 |
基础医学 | 966篇 |
口腔科学 | 748篇 |
临床医学 | 2161篇 |
内科学 | 3583篇 |
皮肤病学 | 637篇 |
神经病学 | 1494篇 |
特种医学 | 622篇 |
外科学 | 3561篇 |
综合类 | 59篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 1323篇 |
眼科学 | 437篇 |
药学 | 518篇 |
中国医学 | 67篇 |
肿瘤学 | 1270篇 |
出版年
2024年 | 97篇 |
2023年 | 567篇 |
2022年 | 270篇 |
2021年 | 525篇 |
2020年 | 865篇 |
2019年 | 395篇 |
2018年 | 862篇 |
2017年 | 769篇 |
2016年 | 938篇 |
2015年 | 906篇 |
2014年 | 1175篇 |
2013年 | 1341篇 |
2012年 | 722篇 |
2011年 | 702篇 |
2010年 | 829篇 |
2009年 | 1035篇 |
2008年 | 604篇 |
2007年 | 459篇 |
2006年 | 541篇 |
2005年 | 390篇 |
2004年 | 287篇 |
2003年 | 266篇 |
2002年 | 225篇 |
2001年 | 273篇 |
2000年 | 206篇 |
1999年 | 243篇 |
1998年 | 289篇 |
1997年 | 291篇 |
1996年 | 329篇 |
1995年 | 300篇 |
1994年 | 195篇 |
1993年 | 140篇 |
1992年 | 160篇 |
1991年 | 185篇 |
1990年 | 90篇 |
1989年 | 144篇 |
1988年 | 121篇 |
1987年 | 90篇 |
1986年 | 101篇 |
1985年 | 100篇 |
1984年 | 93篇 |
1983年 | 81篇 |
1982年 | 81篇 |
1981年 | 49篇 |
1980年 | 56篇 |
1978年 | 55篇 |
1977年 | 49篇 |
1976年 | 39篇 |
1975年 | 45篇 |
1972年 | 37篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
2.
3.
4.
5.
N. S. Hari Narayana Moorthy Sergio F. Sousa Maria J. Ramos Pedro A. Fernandes 《Medicinal chemistry research》2016,25(7):1340-1357
Farnesyltransferase (FTase) is one of the prenyltransferase family enzymes that catalyse the transfer of 15-membered isoprenoid (farnesyl) moiety to the cysteine of CAAX motif-containing proteins including Rho and Ras family of G proteins. Inhibitors of FTase act as drugs for cancer, malaria, progeria and other diseases. In the present investigation, we have developed two structure-based pharmacophore models from protein–ligand complex (3E33 and 3E37) obtained from the protein data bank. Molecular dynamics (MD) simulations were performed on the complexes, and different conformers of the same complex were generated. These conformers were undergone protein–ligand interaction fingerprint (PLIF) analysis, and the fingerprint bits have been used for structure-based pharmacophore model development. The PLIF results showed that Lys164, Tyr166, TrpB106 and TyrB361 are the major interacting residues in both the complexes. The RMSD and RMSF analyses on the MD-simulated systems showed that the absence of FPP in the complex 3E37 has significant effect in the conformational changes of the ligands. During this conformational change, some interactions between the protein and the ligands are lost, but regained after some simulations (after 2 ns). The structure-based pharmacophore models showed that the hydrophobic and acceptor contours are predominantly present in the models. The pharmacophore models were validated using reference compounds, which significantly identified as HITs with smaller RMSD values. The developed structure-based pharmacophore models are significant, and the methodology used in this study is novel from the existing methods (the original X-ray crystallographic coordination of the ligands is used for the model building). In our study, along with the original coordination of the ligand, different conformers of the same complex (protein–ligand) are used. It concluded that the developed methodology is significant for the virtual screening of novel molecules on different targets. 相似文献
6.
7.
8.
9.